Dr. Reddy’s Laboratories has announced significant board-level updates, including the re-appointment of Dr. K P Krishnan and the appointment of Mr. Srikanth Velamakanni as Independent Directors. Additionally, the company has finalized the appointment of Deloitte Haskins & Sells, LLP as Statutory Auditors and M/s Sagar & Associates as Cost Auditors. The board also elevated Mr. Sandeep Khandelwal to Senior Management Personnel, reflecting a strategic strengthening of its leadership and governance frameworks.
Board Composition Updates
In a move to strengthen corporate governance, the company has confirmed the re-appointment of Dr. K P Krishnan as an Independent Director for a second consecutive five-year term, effective from January 7, 2027, until January 6, 2032. Furthermore, the board has appointed Mr. Srikanth Velamakanni, a prominent technology leader and Co-Founder of Fractal, as an Additional and Independent Director. His term is set for five years, spanning July 1, 2026, to June 30, 2031.
Appointment of Auditors
Dr. Reddy’s has formally appointed M/s Deloitte Haskins & Sells, LLP as the new Statutory Auditors. Their term will commence from the conclusion of the 42nd Annual General Meeting (AGM) and continue until the conclusion of the 47th AGM. In parallel, M/s Sagar & Associates has been re-appointed as the company’s Cost Auditors for the Financial Year 2026-27.
Leadership Elevation
The company also announced the elevation of Mr. Sandeep Khandelwal, current Global Generics India Head, to the role of Senior Management Personnel. As part of this transition, effective May 12, 2026, he has been inducted as a member of the Management Council. Mr. Khandelwal has been instrumental in the growth of the India business, overseeing a transformation that saw topline revenue grow from Rs 2,300 crore to Rs 7,000 crore over the past seven years.
Source: BSE
